Evrópusambandið - íslenska - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - manna rotavirus, lifandi dregið úr - immunization; rotavirus infections - bóluefni - rotarix er ætlað til virkrar ónæmis hjá ungabörnum á aldrinum 6 til 24 vikna til að koma í veg fyrir magabólgu vegna rotavirus sýkingar. notkun rotarix ætti að vera byggt á opinberum meðmæli.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - inflúensu, manna - bóluefni - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - sýkingar af völdum sýklalyfja - bóluefni - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - bólusetningar gegn inflúensu - fyrirbyggjandi inflúensu í opinberlega lýst faraldur ástandið. bólusetning gegn heimsfaraldri inflúensu ætti að nota í samræmi við opinbera leiðbeiningar.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - bóluefni - hexyon (dtap-ipv-hb-hib) er ætlað fyrir aðal og orku bólusetningu ungbarna og smábörn frá sex vikna gegn barnaveiki, stífkrampa, stífkrampa, lifrarbólgu b, mænusótt og innrásar sjúkdóma sem orsakast af haemophilus influenzae gerð b (hib). notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) er ætlað fyrir aðal og orku bólusetningu ungbarna og smábörn frá sex vikna gegn barnaveiki, stífkrampa, stífkrampa, lifrarbólgu b, mænusótt og innrásar sjúkdóma sem orsakast af haemophilus influenzae gerð b (hib). notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - bóluefni - Þegar hexa er ætlað fyrir aðal og orku bólusetningu ungbarna gegn barnaveiki, stífkrampa, stífkrampa, lifrarbólgu b, mænusótt og sjúkdómurinn af völdum haemophilus influenzae tegund-b.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - ristil - bóluefni - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. notkun shingrix ætti að vera í samræmi við opinbera tillögur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - kjúklingur - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - sýkingar af völdum sýklalyfja - bóluefni - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. sjá kafla 4. 2 og 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.